Proactive Investor's  Instablog

Proactive Investor
Send Message
Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of... More
My company:
My blog:
  • Positron to build high energy radiopharmaceutical facility in Indiana, focused on vertical expansion 2 comments
    Jun 14, 2011 10:24 AM | about stocks: POSC

    Positron Corp (OTCBB:POSC) said Friday that it signed an informal agreement with the City of Noblesville, Indiana to develop a new, high energy radiopharmaceutical manufacturing facility, a deal that is expected to significantly expand the company's medical imaging capabilities.

    The memorandum of understanding agreement outlines proposed economic incentives for the development of the high energy 70 MeV cyclotron project, which will also see Positron relocate its company headquarters and facilities to Noblesville.

    The $55 million facility will be the largest US-based commercial cyclotron, a device used to make radioactive isotopes, which are in turn used to make radiopharmaceuticals, key tracers or imaging agents used in the field of nuclear medicine in the diagnosis and treatment of many diseases, such as those in cardiology and oncology.

    The Indianapolis-based molecular imaging company, which specializes in the field of nuclear cardiology, sells Attrius positron emission tomography (PET) systems that guide medical and interventional therapy in individual patients with cardiac disease. These systems and patients require radiopharmaceuticals and the source radioisotopes to work.

    Currently, Positron and nuclear cardiology customers rely on the radiopharmaceutical Rubidium, which is derived from strontium, and is produced by the US Department of Energy. This supply of strontium has become limited due to the recent increase in cardiac PET imaging.

    As a result, a recent reduction in the availability of rubidium in January hit the industry at the start of the year, recently returning to near pre-slowdown levels. Positron said, however, it is still on track to sell between 25 and 30 Attrius PET systems in 2011.

    The new supply created by the manufacturing facility is expected to prevent such delays in the future, as the company has taken steps to ensure it can produce medical isotopes and radiopharmaceuticals on its own for years to come, marking the evolution of Positron into a vertically-integrated business.

    The magnitude of energy for the proposed facility will be the highest for commercial isotope production in the US, with facilities of such capacity internationally used for other applications than medical isotopes.

    Under the terms of the agreement, the City of Noblesville is expected to provide roughly $6.7 million, with the State of Indiana shelling out another $1.2 million for training, while Positron will retain 100% control of the cyclotron. Federal funding and project financing are in the works, Positron said, having already received interest from several private equity firms and banks.

    "The securing of critical components of the supply chain realized from this project will be considerable; we have built a solid foundation in our core cardiac imaging products and continue to vertically expand into medical isotopes and radiopharmaceuticals, allowing us to offer a complete solution for cardiac PET imaging," said CEO Patrick G. Rooney.

    If Positron cannot use all the supplies it manufactures at the facility, the company will consider selling them to third parties at a time when prices for radiopharmaceuticals are on the way up, explained Rooney.

    “Having isotopes, radiopharmaceuticals and imaging devices is a key advantage for our business," explained Rooney.

    Indeed, the radiopharmaceutical market is projected to grow to more than $4 billion by 2015.

    The company's development plans, which are anticipated to wrap up in three years, are expected to create more than 80 jobs in Noblesville over the next five years, Positron said, while the city is also set to benefit from the "ripple effects" of the new facility, as additional businesses are anticipated to relocate there in the coming years as a result.

    All parties involved are currently working to sign a definitive agreement for the project, which will include a proposed incentive package, subject to approval from the Council in Noblesville.

    In addition to Positron's PET products, the company has also developed the new PosiRx, which automates and simplifies the dose preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging.

    The new system, launched two months ago, already offers promising potential for the company, with a "great deal of interest" seen, said Rooney.

    Stocks: POSC
Back To Proactive Investor's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • sterlingacterra
    , contributor
    Comments (8) | Send Message
    Good article for the most part yet there was a huge mistake IMO Here is what I noticed:


    The error is an paragraph that reads:


    "If Positron cannot manufactures at the facility, the company will consider selling it to third parties at a time when prices for radiopharmaceuticals are on the way up."


    This is incorrect. What I think the author meant to say was that if Positron finds that it is not fully utilizing the cyclotron, it may consider selling beam time to third parties. At a time when prices for radiopharmaceuticals are on the way up, Positron believes this is a good move in order to secure sufficient supplies for their customers.


    Selling Beam time is something all cyclotrons do ... this helps them to fully utilize the facility and maximize their ROI.


    Can a correction be made because potential investors will not look at this misstatement in a positive light...and the intent of Pat Rooney it's obvious to me was to demonstrate to you the HUGE potential for EXTRA revenue.


    Thanks again!
    14 Jun 2011, 11:05 AM Reply Like
  • Proactive Investor
    , contributor
    Comments (59) | Send Message
    Author’s reply » thanks for the input, we have updated the blog post and original article on our site
    14 Jun 2011, 01:23 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.